Valneva SE (NASDAQ:VALN) Q1 2024 Earnings Conference Call May 7, 2024 9:00 AM ET
Company Participants
Josh Drumm - VP, Global Investor Relations
Thomas Lingelbach - President, CEO & Director
Peter Buhler - CFO
Conference Call Participants
Max Herrmann - Stifel
Rajan Sharma - Goldman Sachs
Evan Wang - Guggenheim
Samir Devani - RX Securities Limited
Ed White - H.C. Wainwright & Co.
Suzanne van Voorthuizen - Van Lanschot Kempen
Maury Raycroft - Jefferies
Josh Drumm
Hello, and thank you for joining us to discuss Valneva's First Quarter 2024 Results and Corporate Update. It's my pleasure to welcome you today. In addition to our press release and analyst presentation, you can find our consolidated financial results for the three months ended March 31, 2024, which were published earlier today, available within the Financial Reports section on our Investor website.
I'm joined today by Valneva's CEO, Thomas Lingelbach; and CFO, Peter Bühler, who will provide an overview and update on our business as well as our key financial results for the first quarter. There will be an analyst Q&A session at the conclusion of the prepared remarks.
Before we begin, I'd like to remind listeners that during this presentation, we will be making forward-looking statements, which are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You can find additional information about these risks and uncertainties in our periodic filings with the Securities and Exchange Commission and with the French market authority, which are also listed on our company website.
Please note that today's presentation includes information provided as of today, May 7, 2024, and Valneva undertakes no obligation to revise or update forward-looking statements except as required by applicable securities laws. With that, it's my pleasure to introduce Thomas to begin today's presentation.
Thomas Lingelbach
Thank you so much, Josh, and good day, everyone, and welcome to this call on our first-quarter key financial results and business update. We had a solid start into 2024, and I'm pleased to present some of our key highlights. We made tremendous progress on the pipeline, of course, chikungunya. We got the favorable ACIP recommendation, CDC adoption. And we see now first commercial revenues kicking in, and I will provide more updates on that.
On Lyme disease, the Phase 3 study, Valneva is progressing according to plan, and we expect the completion of all primary vaccinations very soon. We started, as anticipated, the Zika virus vaccine program, advanced the new second generation candidate into Phase 1, which is another key milestone on our R&D pipeline.